ViaDerma (OTCMKTS:VDRM) Intends to Carry out Additional Internal Quality Control Testing for its New Vitastem Products

A publicly-traded specialty pharmaceutical company, ViaDerma, Inc. (OTCMKTS:VDRM) is actively involved in bringing new products to market while licensing its cutting-edge technology to key players in the pharmaceutical industry in a wide variety of therapeutic areas.

Trading Data     

On Wednesday, VDRM stock moved down 3.68% to $0.0066 with more than 2.65 million shares, compared to its average volume of 1.87 million shares. The stock moved within a range of $0.0060 – 0.0075 after opening trading at $0.0065.

ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products

ViaDerma, Inc. has provided an update regarding its plans to conduct additional internal quality control testing for its new Vitastem products. Manufactured at a contract facility in the United States, Vitastem and Vitastem Ultra have successfully undergone all standard testing required by regulators.

The new and improved Vitastem and Vitastem Ultra are FDA-registered drugs. They fall among the most potent and effective antibiotics available on the market. Take a look:

Vitastem – It kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing. It includes bacteria associated with acne, cuts, scrapes, burns, and secondary infections associated with psoriasis and eczema.

Vitastem Ultra – Bacitracin is the active ingredient. The new formula is clear and colorless as compared to the original, which was brownish, due to the presence of tetracycline as the active ingredient. It won’t stain the skin, fingernails, toenails, or anywhere else it is applied. The new formulation is an excellent alternative for consumers who are allergic or resistant to one or the other.

After a detailed consultation with the company’s manufacturing partners, along with potential purchasers and distributors of the products, it was decided to implement further testing as an additional precautionary measure since both products are using new formulations. This additional testing is expected to be complete within four weeks, with the products being rolled soon after.

President and CEO, Dr. Chris Otiko, stressed the importance of additional testing prior to large-scale distribution, considering both products are a new and improved formulations. He stated that the products have tested well to date, and it is expected those same results will continue sans any problems. But it is always better to implement precautionary measures before fulfilling large purchase orders due to the different formulations as compared to the original. This test will reduce the risk of bigger problems later on.

Key Quote

President and CEO, Dr. Chris Otiko said, “Since both of these products are new and improved formulations, we decided now would be the best time to conduct additional testing before we begin large-scale distribution.”

Technical Data

VDRM stock is trading below the 20-Day and 50-Day Moving averages of $0.0063 and $0.0069 respectively. However, the stock is trading below the 200-Day moving average of $0.0098.